AtriCure vs NovoCure
ATRC and NVCR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRC and NVCR compare
AtriCure is the larger company, worth 2.1 times as much as NovoCure ($2.9B against $1.4B).
AtriCure grew revenue faster over the last twelve months (13.8% versus 12.9% for NovoCure).
AtriCure keeps more of each dollar of sales as profit, with a net margin of 2.5% compared with −16.8% at NovoCure.
AtriCure scores higher on the StockData Score (12 against 9 for NovoCure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRC | NVCR |
|---|---|---|
| Size and price | ||
| Market cap | $2.9B | $1.4B |
| Share price | $56.84 | $11.83 |
| Change, 1 year | 71.9% | 4.1% |
| Change, 5 years | −26.8% | −88.6% |
| Beta (5Y) | 1.26 | 1.57 |
| Employees | 1,350 | 1,605 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 2 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 3 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 189× | – |
| P/S | 4.9× | 1.9× (better) |
| P/B | 5.4× | 3.9× (better) |
| EV/EBITDA | 162× | – |
| P/FCF | 54.6× | – |
| FCF yield | 1.8% (better) | −1.8% |
| Fair value | $8.00 | $16.23 |
| Margin of safety | −611% | 27.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.8% (better) | 12.9% |
| Revenue growth, 5Y average | 20.9% (better) | 5.8% |
| Profitability | ||
| Gross margin | 76.7% | 77.0% (better) |
| Operating margin | 2.9% (better) | −17.2% |
| Net margin | 2.5% (better) | −16.8% |
| FCF margin | 9.0% (better) | −3.4% |
| Return on equity | 2.9% (better) | −35.2% |
| Return on invested capital | 3.9% (better) | −70.8% |
| Financial health | ||
| Debt / equity | 0.11 | 0.07 (better) |
| Net debt / EBITDA | −7.40 | – |
| Interest coverage | 2.9× | – |
| Current ratio | 4.33 (better) | 2.49 |
| Altman Z-score | 10.00 (better) | 0.35 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.26% |
| Shareholder yield | 0.00% (better) | −0.26% |
| Ownership | ||
| Held by institutions | 104% | 88.5% |
| Held by insiders | 4.0% | 3.0% |
| Insider net buying, 12 months | −$4.4M | −$3.4M (better) |
| Short interest, % of float | 10.0% | 11.4% |
Go deeper
- ATRC stock overview
- ATRC income statement
- ATRC valuation and score
- NVCR stock overview
- NVCR income statement
- NVCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.